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Summary 
The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and 
Connecticut Departments of Public Health and Consumer Protection are investigating a fatal case of 
gastrointestinal (GI) mucormycosis caused by Rhizopus oryzae in a premature infant. The infant received 
ABC Dophilus® Powder, a dietary supplement product containing viable microbial ingredients purchased 
from Solgar, Inc., Leonia, New Jersey. The product claimed to have “probiotic” properties and is marketed 
for infants and children. Subsequent testing of the same lot of unopened Solgar ABC Dophilus® Powder 
revealed contamination with Rhizopus oryzae. The purpose of this HAN advisory is to provide awareness 
about this fatal case of GI mucormycosis following ingestion of a contaminated dietary supplement and to 
provide guidance to state health departments and health care providers. Please disseminate this 
information to healthcare workers in neonatal intensive care units, hospital pharmacies, pediatricians, and 
primary care providers, as well as to microbiology and pathology laboratories. 
 
Background 
Mucormycosis is a rare infection caused by mold in the order Mucorales, including Rhizopus spp. GI 
mucormycosis is a very rare manifestation of this disease and occurs when mucormycosis involves the GI 
tract causing signs and symptoms such as: 
 Abdominal pain  
 Abdominal distension 
 Nausea 
 Vomiting 
These symptoms are thought to occur primarily when a susceptible person ingests the fungus, and they 
usually occur in immunocompromised individuals. 
 
In October 2014, a hospital in Connecticut notified CDC and the Connecticut Department of Public Health 
of a fatal case of gastrointestinal mucormycosis in a preterm infant of 29 weeks’ gestation. The infant 
received lot 074 024 01R1 of ABC Dophilus® Powder for four days, beginning on day one of life. ABC 
Dophilus® Powder is a product intended to contain three bacteria, Bifidobacterium lactis, Streptococcus 
thermophilus, and Lactobacillus rhamnosus. The product was purchased from Solgar, Inc., Leonia, NJ, 
and is marketed specifically for infants and children. This product and other dietary supplements thought 
to have probiotic effects have been used in preterm infants on the basis of a recent Cochrane review 
supporting their use for prophylaxis against necrotizing enterocolitis (NEC), a possible complication in 
preterm infants. ABC Dophilus ® Powder is intended for use as a dietary supplement and, as such, is not 
regulated as a drug by the FDA.  FDA has not evaluated the safety of this product for any intended use 
and has not evaluated the veracity of any claims of probiotic or other health benefits.  
(Cochrane review link: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005496.pub4/abstract;jsessionid=7664425A46560
C7617A65EB3779F50C5.f02t02) 
 
This infant subsequently developed clinical signs and symptoms of NEC. Surgical exploration of the 
infant’s abdomen revealed complete GI ischemia from esophagus to rectum, a portion of necrotic bowel 
was resected. Following surgery, the infant developed multiple areas of vascular occlusion, a finding not 
associated with NEC. Shortly thereafter, the infant died.  
 
Histopathologic results from the infant’s necrotic bowel showed angioinvasive fungal infection, consistent 
with mucormycosis. immunohistochemical staining of the tissue block performed locally and at CDC was 
positive when tested with a monoclonal antibody known to react with several mucormycete fungal agents. 
Sequencing of fungal DNA recovered from the tissue block at CDC identified the fungus as Rhizopus 
oryzae, a known cause of mucormycosis.  
 
The hospital initiated an investigation into the infant’s death, including evaluation of the Solgar ABC 
Dophilus® Powder product. Local testing of unopened bottles of lot 074 024 01R1 Solgar ABC Dophilus® 
Powder revealed contamination with mold, confirmed to be Rhizopus oryzae at CDC. On November 14, 
2014, Solgar Inc. issued a voluntary recall (http://www.fda.gov/Safety/Recalls/ucm423219.htm) of ABC 
Dophilus® Powder lots 074024-01R1, 074024-01, and 074024-02 (all with expiration dates of 7/31/15). 
This recall notice includes the instructions that “Consumers who have purchased Solgar ABC Dophilus® 
Powder are urged not to consume the product.” This product was distributed to 29 states, Puerto Rico, 
the United Kingdom, and Israel through pharmacies, retail stores, wholesalers, and online retailers.   
 
Investigation into this fatal case of GI mucormycosis following ingestion of contaminated Solgar ABC 
Dophilus® Powder is ongoing. National case finding efforts are underway to identify additional cases of 
GI mucormycosis following ingestion of this contaminated dietary supplement. 
 
Recommendations 
 Solgar ABC Dophilus® Powder should not be used, especially in infants who may be especially 
susceptible to infection. 
 In considering the use of any dietary supplement, clinicians should consider that the FDA does 
not regulate these products as drugs.   
 
 
Clinical Care 
 Clinicians evaluating: 
o Preterm infants for necrotizing enterocolitis OR 
o Infants who have signs or symptoms of gastrointestinal mucormycosis such as abdominal 
pain, abdominal distension, nausea, or vomiting 
Should review whether Solgar ABC Dophilus® Powder was used as part of the infants’ care.  
 
 If Solgar ABC Dophilus® Powder was consumed by the patient within the previous 30 days, 
clinicians should consider consultation with an infectious disease physician to assist in an 
assessment which may include the following: 
o Aggressive evaluation for a source of infection, including surgical exploration. 
o Empiric treatment with antifungals active against mucormycete infections. 
 
Reporting 
 Clinicians and public health officials are asked to notify their state or local health departments if 
they learn of cases or deaths in the following categories that have occurred since November 1, 
2013: 
o Confirmed or suspected cases of infants with gastrointestinal mucormycosis (diagnosed 
via culture or histopathology). 
OR 
o Unexplained infant deaths within 30 days after ingesting Solgar ABC Dophilus® Powder. 
 
For more information:  
Please consult the CDC website for this investigation: http://www.cdc.gov/fungal/rhizopus-
investigation.html  
 
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international 
organizations. 
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